Showing results (371-380 of 500) with videos related to

Sort By:
Pageof 50
Nature Immunology|July 28, 2009
Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivoXuyu Zhou, Samantha L Bailey-Bucktrout, Lukas T Jeker, et al.
Immunological Reviews|April 1, 1991
Repertoire development and ligand specificity of murine TCR gamma delta cellsJ A Bluestone, R Q Cron, T A Barrett, et al.
The Journal of Experimental Medicine|January 1, 1992
Mechanism of self-tolerance of gamma/delta T cells in epithelial tissueT A Barrett, M L Delvy, D M Kennedy, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 2026
Pharmacology and nonclinical development of teplizumab, a first-in-class immunotherapy for delaying the onset of type 1 diabetesRao N V S Mamidi, Mark Peakman, Wolfgang Schmider, et al.
Nature Immunology|September 29, 2009
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signalBrian T Fife, Kristen E Pauken, Todd N Eagar, et al.
Immunity|February 15, 2015
The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activationMichel DuPage, Gaurav Chopra, Jason Quiros, et al.
The Journal of Experimental Medicine|June 9, 2004
In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetesQizhi Tang, Kammi J Henriksen, Mingying Bi, et al.
Diabetes|May 28, 2005
A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetesKevan C Herold, Stephen E Gitelman, Umesh Masharani, et al.
Diabetes|February 21, 2013
Immune therapy and β-cell death in type 1 diabetesJasmin Lebastchi, Songyan Deng, Amir H Lebastchi, et al.
Immunity|June 21, 2015
Interleukin-33 and Interferon-γ Counter-Regulate Group 2 Innate Lymphoid Cell Activation during Immune PerturbationAri B Molofsky, Frédéric Van Gool, Hong-Erh Liang, et al.
Pageof 50